US 11,780,845 B2
FGFR inhibitors and methods of use thereof
Bakary-Barry Touré, Cambridge, MA (US); Heike Schoenherr, Cambridge, MA (US); Fabrizio Giordanetto, New York, NY (US); Demetri T. Moustakas, Cambridge, MA (US); and Brandi M. Hudson, Cambridge, MA (US)
Assigned to Relay Therapeutics, Inc., Cambridge, MA (US); and D.E. Shaw Research, LLC, New York, NY (US)
Filed by Relay Therapeutics, Inc., Cambridge, MA (US); and D.E. Shaw Research, LLC, New York, NY (US)
Filed on Jan. 31, 2023, as Appl. No. 18/162,127.
Application 18/162,127 is a continuation of application No. 17/595,257, previously published as PCT/US2020/032474, filed on May 12, 2020.
Claims priority of provisional application 63/011,469, filed on Apr. 17, 2020.
Claims priority of provisional application 62/993,957, filed on Mar. 24, 2020.
Claims priority of provisional application 62/846,991, filed on May 13, 2019.
Prior Publication US 2023/0192709 A1, Jun. 22, 2023
Int. Cl. C07D 487/04 (2006.01); C07D 487/22 (2006.01); C07D 491/048 (2006.01); C07D 498/22 (2006.01); C07D 519/00 (2006.01); C07D 498/02 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 487/22 (2013.01); C07D 491/048 (2013.01); C07D 498/02 (2013.01); C07D 498/22 (2013.01); C07D 519/00 (2013.01)] 2 Claims
 
1. A compound, which is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.